Is now a good time to buy stocks? Given that we have yet to see the full economic impact of the COVID-19 pandemic -- and that equity markets may see even more turbulent days ahead -- some might choose to refrain from purchasing stocks altogether. However, long-term investors may want to take this opportunity to buy stocks at reasonably attractive valuations. After all, even after its recent rebounds, the S&P 500 is still down by 13.6% year to date, and many stocks now sport much lower price-to-earnings ratios than they did at the beginning of the year.
Even without the incentive of more attractive valuations, though, some stocks are worth serious consideration. Here are two stocks you should consider buying if you have an extra $1,000 laying around: CRISPR Therapeutics (NASDAQ: CRSP) and Exelixis (NASDAQ: EXEL).
CRISPR Therapeutics develops treatments that employ gene editing, a technology that replaces the defective genes responsible for causing certain illnesses with correct versions of the gene. The company currently has several exciting products in its pipeline including a trio of potential cancer treatments, CTX110, CTX120, and CTX130. But all three are still in early testing phases, and none will hit the market anytime soon if they earn approval at all.